Abstract Number: 1151 • ACR Convergence 2024
Clinical Characterization and Recurrence Prediction Model for Immune-Mediated Necrotizing Myopathy
Background/Purpose: The primary objective of this study was to comprehensively analyze the clinical characteristics of immune-mediated necrotizing myopathy (IMNM) and develop a reliable recurrence prediction…Abstract Number: 1425 • ACR Convergence 2024
Sjögren’s Syndrome and Interstitial Lung Disease: Experience in a Collaborative Rheumatology-Pulmonology Clinic
Background/Purpose: Pulmonary lung disease represents the most prevalent extra-glandular manifestation in patients with Sjögren’s syndrome (SS). Notably, interstitial lung disease (ILD) stands out as the…Abstract Number: 1617 • ACR Convergence 2024
Persistence of Imaging Abnormality in Patients with Large Vessel Vasculitis Despite Clinical Remission
Background/Purpose: Aim of our study was to evaluate the persistence of imaging abnormalities in patients with Takayasu (TAK) and large vessel giant cell arteritis (LV-GCA)…Abstract Number: 1750 • ACR Convergence 2024
Safety and Preliminary Efficacy of CD19 CAR-T Cell Treatment in Rheumatic Disease – Data from the First Part of the Phase I/II CASTLE Basket Study
Background/Purpose: Systemic autoimmune diseases are based on an aberrant activation of B cells. Autologous CD19 chimeric antigen receptor (CAR) T cells allow deep depletion of…Abstract Number: 1838 • ACR Convergence 2024
M5542: A Potent CD80, CD86, and OX40L Antagonist Fusion Molecule for the Treatment of Autoimmune Diseases
Background/Purpose: Overactive adaptive immune responses contribute to many autoimmune diseases such as systemic lupus erythematosus (SLE). Chronically activated autoreactive T-effector cells play a pivotal role…Abstract Number: 1930 • ACR Convergence 2024
Clinical Significance of Positive ENA Testing in ANA-Negative Patients: A Retrospective Analysis of Rheumatologic Diagnoses
Background/Purpose: On the basis of consensus methodology and literature review, the ACR has recommended that antibodies to extractable nuclear antigens (ENA), also known as subserologies…Abstract Number: 2065 • ACR Convergence 2024
Proposed Pathways Involved in the Pathogenesis of Juvenile Dermatomyositis (JDM)
Background/Purpose: JDM is an autoimmune disease of skin and muscle. We investigated genetic factors, autoantibodies, and clinical features in JDM.Methods: Subjects came from 2 large…Abstract Number: 2385 • ACR Convergence 2024
Increased Type I Interferon Inducible Genes Expression in the Peripheral Blood of Patients Presenting Cutaneous Lupus Erythematosus Manifestations
Background/Purpose: Cutaneous Lupus Erythematosus (CLE) is a chronic autoimmune skin disease characterized by a spectrum of cutaneous manifestations resulting from immune dysregulation and inflammation. While…Abstract Number: 2530 • ACR Convergence 2024
Single-cell Multi-omics Analysis of Reactive Lymph Nodes, Affected Tissues, and Blood Reveals a Naive-like CD4+TRAIL+ T Cell Population That Differentially Directs Effector Anti-nuclear Antigen Reactive Responses in Patients with Sjogren’s Syndrome and Systemic Sclerosis
Background/Purpose: Recognition of self-peptides by autoreactive CD4+ T-cells is central to the disruption of immune tolerance. Although systemic autoimmune diseases such as Sjogren’s syndrome (SjS)…Abstract Number: 2661 • ACR Convergence 2024
Changes in Krebs Von Den Lungen 6 Levels (∆KL6) Predict Fibrosing Progression of Interstitial Lung Disease in Patients with an Underlying Connective Tissue Disease (CTD-ILD)
Background/Purpose: Krebs von den Lungen-6 (KL6) is a mucin-1 glycoprotein produced by type 2 alveolar epithelial cells , which increase at peripheral blood show a…Abstract Number: 0005 • ACR Convergence 2024
Autoantibodies Identified in Myositis-Specific Autoantibody Negative Juvenile Myositis Patients
Background/Purpose: Myositis autoantibodies are important clinical biomarkers however, around 40% of patients with juvenile myositis (JM) are classified as ‘autoantibody negative’ (1) and therefore cannot…Abstract Number: 0088 • ACR Convergence 2024
Profound B Cell Depletion and Repopulation with Predominantly Naïve B Cells in Non-Human Primates Achieved Through a Novel In Vivo CD8-Targeted Lipid Nanoparticle mRNA CAR
Background/Purpose: Ex vivo chimeric antigen receptor (CAR) T cell therapies have revolutionized cancer treatment and are demonstrating durable clinical efficacy in various autoimmune disease indications.…Abstract Number: 0247 • ACR Convergence 2024
Enhanced Immunogenicity of the Recombinant Herpes Zoster Vaccine After One-Week of Mycophenolate Mofetil Discontinuation in Patients with Autoimmune Rheumatic Diseases: Interim Results from a Prospective Randomized Phase 4 Study
Background/Purpose: Recently, it was demonstrated that temporarily halting mycophenolate mofetil (MMF) for 1-week post-COVID-19 vaccination in systemic lupus erythematosus (SLE) patients improved humoral response, without…Abstract Number: 0311 • ACR Convergence 2024
Investigation of Sarcoidosis-associated Neuropathy: Challenges with Diagnosis of Small Fiber Neuropathy
Background/Purpose: Small fiber neuropathy (SFN) is an underrecognized complication of sarcoidosis which can significantly impair individuals’ physical functioning and quality of life. Diagnosis includes both…Abstract Number: 0475 • ACR Convergence 2024
Rheumatoid Arthritis – Progressive Interstitial Lung Disease with Abatacept: Data from a Large National Multicenter Cohort
Background/Purpose: Interstitial lung disease (ILD) is a severe extra-articular manifestation of rheumatoid arthritis (RA). Abatacept (ABA) has demonstrated effectiveness in the treatment of RA-ILD, regardless…
- « Previous Page
- 1
- …
- 8
- 9
- 10
- 11
- 12
- …
- 80
- Next Page »